New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients ... (Business Wire via Yahoo! Finance) PDF Print

CHESHIRE, Conn.----Two separate case reports published today in the New England Journal of Medicine examine the investigational use of Soliris ® , a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. , in patients with a rare and severe inflammatory disease called atypical Hemolytic Uremic Syndrome .

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.